Tumor cells from a patient with B-cell lymphoma were fused with a mouse myeloma cell line. A set of heterohybridomas was thus derived, each of which represented a separate clonal derivative from the tumor cell population. The immunoglobulins secreted by these cell lines reacted variably with a panel of anti-idiotypic antibodies, indicating that the tumor was heterogeneous; however, one antibody, 4D6, reacted strongly with the product of all the heterohybridomas. cDNA for the immunoglobulin heavy chain variableregion genes expressed in these heterohybridomas was cloned and sequenced. Comparison of these sequences indicated that the cells expressing them were clonally related but that they had undergone considerable mutation. Despite mutation, the cells in this tumor population continued to express a functional immunoglobulin molecule and to retain, over a span of 3 years, the idiotypic determinant defined by the 4D6 monoclonal antibody. Thus a selective force existed within the host to retain tumor cells bearing an immunoglobulin molecule with a particular idiotypic structure.
ticular idiotypic structure.
The immunoglobulin genes expressed by B lymphocytes are the product of rearrangements between segments of DNA encoding the variable (V) and constant (C) regions of the protein chains. Diversity in the immunoglobulin repertoire is accounted for partly by the large number of V gene segments in the germ line and partly by a process of somatic mutation of the V gene that is chosen by each cell (1) . Thus, a clone of B cells, with a particular set of VDJ and VJ rearrangements (where V, D, and J represent variable, diversity, and joining gene segments) of the heavy and light chain genes, respectively, can evolve due to the combined effects of V-region mutation and selection by antigens and by regulatory influences within the body.
Tumors of B lymphocytes, once thought to be frozen at particular stages of differentiation, are now appreciated to be capable of evolution under the influence of physiologic regulatory forces. Certain types of human B-cell malignancies seem to undergo a process of mutation within their rearranged immunoglobulin genes that resembles the process occurring in normal B cells. Currently it is not known if the immunoglobulin produced by these malignant B-cell clones plays any role in the survival of these cells within the host. We present evidence here that this is the case. Somatic mutation of immunoglobulin V genes can present a major obstacle for immunotherapy directed against the surface immunoglobulin of human B-cell lymphoma. A previous report (2) described nucleic acid sequences of immunoglobulin V genes expressed by the malignant B-cell tumor of a patient treated with an anti-idiotypic (anti-Id) monoclonal antibody (2) . That tumor, a follicular lymphoma, had initially responded to the immunotherapy with shrinkage of its mass, but it subsequently regrew despite continued antibody therapy (3) . The escaping tumor cells no longer reacted with the anti-Id antibody. Analysis of the genes coding for the variable region of the heavy chain (VH genes) in this tumor showed that extensive somatic mutation had occurred even prior to therapy. A subset of cells bore a mutation resulting in a single amino acid change in VH complementarity-determining region 2 (CDR 2) that abolished the antigenic determinant recognized by the anti-Id antibody.
Here we present a similar analysis of nucleic acid sequences of the VH genes expressed by a malignant lymphoma of a patient whose tumor did not escape the effect of anti-Id therapy (4). Our results show that even this completely responding tumor population was subject to immunoglobulin mutation but that the target idiotope was maintained within the host.
METHODS
Heterohybridomas and Anti-Id Antibodies. Tumor cells [secreting IgM(X)] separated from the peripheral blood of patient PK were fused to the non-immunoglobulin-secreting mouse myeloma cell line NS-1/Ag4 (5, 6). The heterohybridoma clones that secreted human immunoglobulin were identified by radioimmunoassay as previously described (7) . Heterohybridoma clone K6H6 lost production of the murine NS-1 light chain and secreted only human IgM(A). This IgM was isolated by affinity chromatography and used for monoclonal anti-Id antibody production as described (8) . A number of different monoclonal anti-Id antibodies were produced against the protein secreted by heterohybridoma K6H6. Each of these antibodies reacted with the K6H6 protein but not with a panel of 12 human IgM proteins derived from other patients. The antibody 4D6 (IgG2b), which gave the strongest reactivity with the K6H6 protein, was chosen for immunotherapy. It showed no reactivity with tumor cells from 10 unrelated lymphoma patients or with normal B cells but showed strong reactivity with the tumor cells from patient PK.
Crossmatching (2) or with a labeled cDNA clone obtained from heterohybridoma K5C7. The cDNA inserts were subcloned into bacteriophage vector M13mpl9 (9) and sequenced (10) . RESULTS 
AND DISCUSSION
Tumor cells were isolated from a sample of peripheral blood obtained from the patient in 1978. These cells were fused with cells of the nonsecreting mouse myeloma line NS-1/Ag 4 (5, 6) , and the resulting heterohybridoma clones were screened by radioimmunoassay for secretion of immunoglobulin of the appropriate human chain types [IgM(X)]. A detailed analysis of heavy and light chain production by some of these clones has been published (7). In order to produce anti-Id antibodies, mice were immunized with the idiotype-bearing immunoglobulin from one of the heterohybridomas, K6H6, which secreted only human ,u and X immunoglobulin chains. Hybridomas from the immunized mice were screened for reactivity with idiotypic determinants on the tumor-derived IgM molecule (8) . One of several anti-Id antibodies, 4D6 (IgG2b), showed both the highest avidity for the IgM protein and the best reactivity with tumor cells from the patient. This antibody was used to treat the patient in 1981 and a complete remission of the tumor occurred (4) . The patient has subsequently remained free of his tumor.
Each of the heterohybridomas represented a clonal isolate from the tumor cell population that existed in the patient 3 years prior to therapy. We therefore made use of these cell lines to examine the possible genetic heterogeneity of the tumor. Our primary question was whether the immunoglobulin molecule, the target for the therapeutic anti-Id antibody, was stable and devoid of mutations in this particular patient. If the immunoglobulin genes expressed by this patient's tumor cells were not subject to somatic mutation, that might explain why this therapy was ultimately more effective than it was in other patients, where extensive immunoglobulin V-region mutations have been documented.
Idiotypic Heterogeneity of the Tumor Cells. The analysis of heterogeneity began at the level of serology. Multiple anti-Id antibodies had been produced in addition to the one that was used for therapy. A panel of five such anti-Id antibodies was tested for reactivity against the IgM products of six independent heterohybridomas made from the tumor ( Table 1) . Each of the heterohybridomas secreted human IgM(X) presumed at this point to be derived from the tumor.
Of the five anti-Id antibodies, only monoclonal antibody 4D6, which was used in immunotherapy, reacted strongly with all six heterohybridoma products. Two of the antibodies, 2B8 and 7B4, reacted weakly with all products. Antibodies 4G1 and 3D5 failed to react with the IgM produced by heterohybridoma K6F5 and reacted moderately with the five other heterohybridoma products. From this analysis it is clear that the antibody 4D6, which was used for therapy, recognized an idiotope present in the IgM molecules produced by all six heterohybridomas, whereas two antibodies reacted with idiotopes that were variably represented in the heterohybridoma products.
To confirm that the six heterohybridomas arose from a single tumor clone, we performed Southern blot analysis (11) using the CA and JH probes (2) to test DNA extracted (12) from each of the heterohybridomas. For all clones except K6F5, the size of the restriction fragment representing the functionally rearranged heavy chain gene was the same (data not shown). Although clone K6F5 did not seem to be a member of the original tumor clone by this Southern blot analysis, its immunoglobulin product reacted indistinguishably from those of all the other clones with antibodies 4D6, 2B8, and 7B4 (Table 1) ; therefore, we thought it possible that clone K6F5 had undergone a somatic mutation that resulted in the mobility change of the band representing the rearranged gene. The data from the Southern blot analysis, together with the variability of monoclonal anti-Id reactivity with these clones, suggested the existence of somatic mutations in the immunoglobulin genes of this patient's tumor cells.
Genetic Heterogeneity of the Tumor Cells. Next, we determined the nucleotide sequences of the expressed immunoglobulin genes from the six heterohybridoma clones. For this Proc. Nati. Acad. Sci. USA 84 (1987) 5055 
GTC GGA AAT TAT ACG GGG ACC GTT GAG TAG TGG GGC GAG GGA ACC CTG GTC ACC GTC TCC TCA 
105-and the same D segment, and their V-D and D-J junctions were identical. However, each of the six sequences was unique. The K6H6 sequence was identical to the consensus sequence. Although clones K4B8 and K5B8 had the same sequence in their protein-coding regions, clone K5B8 had one nucleotide deletion in its 5' untranslated region. Clone K6F5, which had the most unusual reaction with the anti-idiotypic antibodies (Table 1) and which had a difference in its heavy chain DNA restriction fragment pattern, had a VH amino acid sequence that differed from that of the K6H6 prototype by only a single amino acid, in framework region 1 (FR 1) at position 15. This amino acid position is usually invariant in heavy chain V-region subgroup III (13) , to which these VH sequences belong. The VH gene from K6F5 had an additional amino acid replacement in its leader peptide, which would not have affected its reactivity with the anti-Id antibodies.
In contrast to clone K6F5, which was expected to be most different from other clones and was found to be very homologous in its heavy chain V-region sequence, clone K5G5, which had shown no difference either in its restriction fragment pattern or in its antibody reactivity pattern, had several nucleotide substitutions. Two of these substitutions resulted in amino acid coding changes in its D segment. These two amino acid replacements, at positions 98 and 100 in CDR 3, did not affect binding to the anti-Id antibodies (Table 1) and therefore were not part of the idiotope recognized by these antibodies. The two other complementarity-determining regions of this clone were well conserved; CDR 1 and CDR 2 contained no mutations. It is therefore possible that one or both of these stable complementarity-determining regions contributed to the idiotypic determinant recognized by 4D6, the monoclonal antibody used for therapy.
Clonal Evolution of the Tumor. From inspection of the VH sequences in Fig. 1 , it is clear that many of the same mutations were present in more than one clonal isolate. It is formally possible that certain positions in the sequence had a propensity to mutate and that these repetitive mutations occurred as separate and independent events. It is also possible that selective forces within the host favored the retention of clones with particular mutations that arose independently. An example of this has been described in normal B-cell clones responding to the antigen nitrophenyl (14) . However, a plausible explanation for mutations in common is a stepwise evolution of the clone through successive mutations in series. The simplest relationship between the six clonal isolates of the tumor, according to their VH sequences, is displayed in Fig. 2 . All the clones could have been derived from a hypothetical precursor that employed the germ-line J4 gene segment. A single mutation in the J region, at amino acid position 105, could have given rise to clone K6H6. Subsequent stepwise mutations could then have produced derivatives with the sequences as shown. Of course, the resulting population of cells would be determined by the evolutionary history of the clone, which would reflect both the mutational process as well as the effects of selection. Evidence for Host Selection. A summary of the nucleotide changes in these VH genes is given in Table 2 . All three framework regions had somatic mutations; however, few of the mutations resulted in amino acid replacements. In framework regions, the overall frequency of replacement mutations (as a percentage ofpotential substitutions for all codons) was 33%, compared to an expected value of 73% (Table 2 ). This frequency is very similar to that obtained in a previous study of the VH genes of a patient whose tumor escaped anti-Id therapy (2) , where a frequency of 30% replacement mutations in the framework regions was found. In the clones analyzed here, CDR 1 and CDR 2 had no amino acid replacement mutations. CDR 3 had equal numbers of silent and replacement mutations, but all of these replacement mutations were found in a single clone. Altogether, the observed percentage of productive mutations in complementarity-determining regions was much lower than the expected value (43% vs. 75%). This result is different from that obtained in the study of the anti-Id-resistant tumor (2) , where the percentage of replacement substitutions in one complementarity-determining region was equal to or even higher than the expected value. The results presented here indicate that a selective force was operating to favor cells that preserved certain amino acid sequences in the V region of their immunoglobulin heavy chains. It should be noted that the clones analyzed here had been selected twice, once in the host, where the selection might have been due to an antigen or to an idiotypic network, and once in the laboratory when clones were chosen that secreted intact immunoglobulin molecules. However, >95% of the tumor cells taken from the patient on multiple occasions spanning a period longer than 3 years expressed both 4 and X immunoglobulin chains, and therefore we assume that our choice of immunoglobulinproducing heterohybridomas did not introduce a bias in the data.
Selective forces within the host could have included antigens or idiotypic networks of either a humoral or cellular nature. We do not know whether or not the immunoglobulin produced by this tumor reacted with any antigen within the host. However, numerous examples exist of myeloma proteins that bind autoantigens such as erythrocyte antigens, lipoproteins, coagulation factors, other serum proteins, cytoskeletal proteins, or nuclear antigens (15) . Most of those have been discovered because of the clinical pathologic manifestations of the tumor immunoglobulin-autoantigen interaction. Are these antigen-binding activities important in driving the proliferation of their respective tumors or do they merely represent gratuitous activities of the product of a plasma cell ity. If antigen constitutes a driving or a selecting force, then variants that did arise as a consequence of an active mutational process would nevertheless retain their binding activity for the antigen. Our analysis of the PK tumor indicated that an extremely high prevalence of mutations existed in the tumor cell population when it was originally sampled-six out of six randomly selected clones were different from each other. At that point in time the total size of the population was at least 5 x 1011 cells. The rate of mutation cannot be determined because there is no way of knowing how many cell divisions had occurred in the tumor. However, it is clear from the data that strong selective forces were operative in the host to favor cells that did not alter the amino acid coding sequence oftheir VH genes. With such a high prevalence of VH mutants, it is remarkable that a simple genealogic relationship could be constructed for the six randomly selected cells. More remarkably, 3 years after the sample of the tumor analyzed here was obtained, a single monoclonal anti-Id antibody continued to react with the majority of this cell population and could mediate the elimination of the tumor.
In summary, our data indicate that human B-cell tumors are subject to an active mutational process in their expressed immunoglobulin V-region genes similar to that of normal B cells undergoing expansion in response to antigens (14, (16) (17) (18) (19) (20) (21) (22) . However, a high degree of mutation does not result in a loss of immunoglobulin expression or even in the loss of particular idiotypic determinants, provided the idiotope is maintained by strong selective forces within the host.
